Prevention and control measures for rotavirus
Two rotavirus vaccines were authorised for prevention of rotavirus gastroenteritis in 2006. Authorised vaccines provide a high level of protection against severe disease in need of medical attention. Evidence suggests that rotavirus vaccination should be initiated before 12 weeks of age and can be administered together with other infant vaccines.
Preventive measures for infectious diseases
Find out more about prevention and control of vaccine-preventable diseases; guidance, action plans, communication plans and campaigns, vaccination coverage, childhood vaccination etc
Prevention and control measures for yellow fever
A safe, effective and inexpensive yellow fever attenuated vaccine, known as YF 17D, has been used for more than half a century. The vaccine is highly effective. Travelers to endemic areas are advised to check their vaccination status and get vaccinated if necessary.
Vaccine-preventable diseases and immunisation: Core competencies
This report outlines the development of a competency framework covering key knowledge, skills and attitudes critical for the prevention and control of vaccine-preventable diseases and immunisation.
Immunity following influenza disease and administration of influenza vaccines
For infants the first encounter with influenza viruses commonly occurs in their first or second winter season. Subsequently, each individual acquires a number of influenza infections throughout life. It is expected that up to ~15% of a European population in a temperate climate is infected with influenza in any winter season with higher percentages in children and lower in older people.
Review of the scientific literature on drivers and barriers of seasonal influenza vaccination coverage in the EU/EEA
The report aims to provide a critical review of evidence on the barriers and drivers of seasonal influenza vaccination coverage in the EU/EEA. The report focuses on high-risk groups where high coverage of seasonal flu vaccination is most important. The 2009 Council of the European Union Recommendation on seasonal influenza vaccination encourages countries to implement measures that would increase seasonal influenza vaccination uptake to at least 75% for defined older age groups, and, if possible, for other risk groups. In support of this, the ECDC report summarises the evidence on what are the barriers and what are the drivers for seasonal influenza vaccination by each risk group
Interim technical guidance on public health use of influenza antivirals during influenza pandemics
Antiviral drugs are an important addition to the public health arsenal against influenza. This interim guidance discusses the options for their effective use, especially during a pandemic.
Interim technical guidance on use of specific pandemic influenza vaccines during the H1N1 2009 pandemic
This interim guidance outlines the possible strategies that countries may wish to adopt in the deployment of a pandemic-specific vaccine, considering the two objectives of vaccination: protecting those at greatest risk of severe disease and maintaining essential services.
The use of vaccines for prevention of seasonal and pandemic influenzaArchived
On 3 October 2011 European Centre for Disease Prevention and Control (ECDC) and representatives of the European Vaccine Manufacturers met at ECDC in Stockholm for a regular scheduled meeting about the use of vaccines for prevention of seasonal and pandemic influenza. ECDC Director Marc Sprenger opened the meeting and ECDC influenza experts held different presentations, such as burden of influenza disease in the EU, risk groups for severe influenza disease, personal protective measures, pandemic influenza preparedness, seasonal influenza vaccines, communication.
The Declarations of Interest for ECDC Influenza Staff and the ECDC Director are available here under ECDC Transparency.